[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.236.145.124. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correction
November 2015

Misspelled Author Name

Author Affiliations
 

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Oncol. 2015;1(8):1172. doi:10.1001/jamaoncol.2015.4229

In the Original Investigation titled “Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial,”1 published online April 30, 2015, the byline contained a typographical error. The name should have appeared as Paolo Nuciforo, MD. This article was corrected online. This article was also corrected on May 22, 2015,2 for errors in Figure 2.

References
1.
Salgado  R, Denkert  C, Campbell  C,  et al.  Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial.  JAMA Oncol. 2015;1(4):448-454.PubMedGoogle ScholarCrossref
2.
 Error in figure [correction].  JAMA Oncol. 2015;1(4):544.PubMedGoogle Scholar
×